Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

NCT02445131 PHASE2 COMPLETED

The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients

Details

Lead sponsor	German CLL Study Group
Phase	PHASE2
Status	COMPLETED
Enrolment	48
Start date	Thu May 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Mar 09 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chronic Lymphocytic Leucemia

Interventions

• Bendamustine
• GA101
• CAL-101

Countries

Germany